Weight loss from Lilly's Zepbound reversed after stopping treatment,
study shows
Send a link to a friend
[December 12, 2023]
(Reuters) -Patients on Eli Lilly's weight-loss drug Zepbound
substantially regained weight nearly a year after stopping treatment,
according to full results of a study published on Monday.
The data, published in the journal JAMA, showed patients who were obese
and without diabetes experienced a 14% weight regain nearly a year after
they switched to a placebo from an eight-month course of Lilly's
Zepbound.
Meanwhile, those who continued the treatment experienced an additional
5.5% weight reduction during the 52-week period, data from the study
showed.
Shares of Eli Lilly fell over 4% in morning trading.
Lilly's tirzepatide is sold under brand name Zepbound for weight loss
and has been available as Mounjaro for type 2 diabetes.
The drugs, along with Novo Nordisk's Wegovy and Ozempic, belong to a
class of obesity and weight loss treatments that target the GLP-1
hormone which triggers the feeling of fullness in the body after eating.
Patients discontinuing the use of weight-loss drugs such as Wegovy risk
regaining their original body weight in about five years, a Novo Nordisk
official said in March.
Lilly had published some details from the trial in July.
Analysts had said, at the time, the results showed patients need to
continue therapy with GLP-1 drugs for a longer term.
[to top of second column]
|
Lilly Biotechnology Center is shown in San Diego, California,
U.S. March 1, 2023 after Eli Lilly and Co on Wednesday said it will
cut list prices by 70% for its most commonly prescribed insulin
products, Humalog and Humulin, beginning from the fourth quarter of
this year. REUTERS/Mike Blake/File Photo
"We await additional longer-term
data to assess the effects of tirzepatide and other incretin-based
therapies after multiple years of continuous therapy," where there
is a risk of rapidly diminishing response to such drugs, Goldman
Sachs analysts had said in July.
Over the course of the entire treatment period of 88 weeks, patients
who continued Lilly's drug showed 25.3% weight loss. The overall
weight reduction was 9.9% during the entire study period for
patients who switched to placebo after 56 weeks.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli
and Krishna Chandra Eluri)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |